Quarterly ResultMay 13, 2026, 06:32 AM
Aprea Therapeutics Secures $30M; APR-1051 Shows Partial Responses
AI Summary
Aprea Therapeutics reported Q1 2026 financial results, highlighted by the closing of an oversubscribed $30 million private placement. This financing extends the company's cash runway into Q1 2028 and will support the ongoing development of APR-1051, which showed two partial responses with encouraging tolerability in its Phase 1 ACESOT-1051 trial. The company also provided updates on its ATRN-119 program and announced a new Chief Medical Advisor.
Key Highlights
- Closed oversubscribed $30 million private placement on March 31, 2026.
- Observed two partial responses in Phase 1 ACESOT-1051 trial for APR-1051.
- Cash and cash equivalents totaled $46.5 million as of March 31, 2026.
- Anticipates cash runway into Q1 2028.
- Reported Q1 2026 net loss of $3.3 million, or ($0.22) per basic share.
- Q1 2026 operating loss was $3.4 million.
- R&D expenses decreased to $1.6 million in Q1 2026.
- Enrollment in ACESOT-1051 to expand to at least 50 USC patients.
Price Impact
More from APRE